PT  - JOURNAL ARTICLE
AU  - Butler, Andrew A.
AU  - Agarwal, Geetika
AU  - Malmstrom, Theodore K.
AU  - Miller, Douglas K.
AU  - Nguyen, Andrew D.
AU  - Morley, John E.
TI  - Increased risk of cognitive impairment and hyperglycemia-related mortality in late middle-aged African Americans with low serum adropin levels
AID  - 10.1101/2021.12.09.21267550
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.09.21267550
4099  - http://medrxiv.org/content/early/2021/12/11/2021.12.09.21267550.short
4100  - http://medrxiv.org/content/early/2021/12/11/2021.12.09.21267550.full
AB  - Recent data implicate the secreted peptide adropin in the physiology of aging. In mice, adropin improves glucose homeostasis. In humans, adropin is highly expressed in brain tissues, and correlates positively with transcriptomic signatures of mitochondrial and synaptic functions. Adropin improves performance of old mice in cognitive tests requiring learning and memory. While detected in the human circulation, no studies have investigated relationships between adropin, cognitive decline and aging. We compared serum adropin concentrations with Mini-Mental State Exam (MMSE) and animal naming test results from a cohort study of African Americans in late-middle age (baseline ages 49-65y, n=357). Using the lowest quintile of the MMSE to identify participants at risk for mild cognitive impairment (MCI) indicated lower serum concentrations (2.95±1.32 ng/ml vs. 3.31±1.56, P<0.05). Grouping into bins using 1-ng/ml increments in serum adropin concentrations further indicated an association between very low serum adropin concentrations and MCI. Using fructosamine as an indicator of moderate-term glucose levels suggested low serum adropin concentration correlate with increased risk of 10-year all-cause mortality in situations of poor glucose control. In summary, these data suggest low circulating adropin concentrations identify late-middle aged people at risk for cognitive impairment, and for all-cause mortality in situations of poor glucose control.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAAB was supported by the NINDS, NIH (R21NS108138). AAB and ADN acknowledge financial support provided by Saint Louis University. African American Health was supported by a grant from the National Institute on Aging (R01 AG010436 to DKM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All study procedures were approved by the Institutional Review Board at Saint Louis University and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors